<p>阿默普莱斯金融公司在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股增加了 21.0%。该基金在本季度购买了额外的 29,118 股后，持有 167,746 股该医疗器械供应商的股票。截至最近报告期末，阿默普莱斯金融公司持有的西氏医药服务公司约占 0.23%，价值 54,947,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他几家对冲基金也增加或减少了在 WST 的持股。Quadrant Capital Group LLC 在第四季度将其在西氏医药服务公司的股份增加了 5.4%。Quadrant Capital Group LLC 现在拥有 626 股该医疗器械供应商的股票，价值 205,000 美元，此前在上个季度购买了额外的 32 股。Baron Wealth Management LLC 在第四季度将其在西氏医药服务公司的持股增加了 1.9%。Baron Wealth Management LLC 现在拥有 1,926 股该医疗器械供应商的股票，价值 631,000 美元，此前在该期间购买了额外的 35 股。Exchange Traded Concepts LLC 在第四季度将其在西氏医药服务公司的持股增加了 18.9%。Exchange Traded Concepts LLC 现在拥有 239 股该医疗器械供应商的股票，价值 78,000 美元，此前在上个季度购买了额外的 38 股。Lake Street Advisors Group LLC 在第四季度将其在西氏医药服务公司的持股增加了 5.8%。Lake Street Advisors Group LLC 现在拥有 711 股该医疗器械供应商的股票，价值 233,000 美元，此前在该期间购买了额外的 39 股。最后，Cornerstone Planning Group LLC 在第四季度将其在西氏医药服务公司的持股增加了 57.1%。Cornerstone Planning Group LLC 现在拥有 110 股该医疗器械供应商的股票，价值 38,000 美元，此前在上个季度购买了额外的 40 股。目前 93.90% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>WST 已成为多份研究报告的主题。StockNews.com 在 2 月 27 日的报告中将西氏医药服务的股票评级从 “买入” 下调至 “持有”。Stephens 在 4 月 21 日的研究报告中将西氏医药服务的评级上调至 “强力买入”。Evercore ISI 在 3 月 18 日的研究报告中开始覆盖西氏医药服务。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 275.00 美元的目标价。德意志银行将西氏医药服务的股票评级从 “持有” 上调至 “买入”，并在 2 月 14 日的研究报告中为该公司设定了 250.00 美元的目标价。最后，KeyCorp 在 2 月 14 日的研究报告中将西氏医药服务的股票目标价从 470.00 美元下调至 325.00 美元，并对该股票给予了 “增持” 评级。两位投资分析师对该股票给予了持有评级，六位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，西氏医药服务的平均评级为 “适度买入”，共识目标价为 332.50 美元。</p>
<ul>
<li>今年将推动标准普尔 500 表现的因素是什么？</li>
</ul>
<p><strong>获取我们对西氏医药服务的最新分析</strong></p>
<h2>西氏医药服务股票下跌 0.6%</h2>
<p>西氏医药服务（NYSE:WST）周五开盘价为 213.39 美元。该公司的 50 日移动平均价格为 216.55 美元，200 日移动平均价格为 278.35 美元。公司市值为 153.3 亿美元，市盈率为 31.90，PEG 比率为 6.74，贝塔值为 1.14。公司的债务与股本比率为 0.08，流动比率为 2.79，速动比率为 2.23。西氏医药服务公司的一年低点为 187.43 美元，一年高点为 367.71 美元。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西氏医药服务（NYSE:WST - 获取免费报告）最近在 4 月 24 日发布了其财报。该医疗器械供应商报告本季度每股收益为 1.45 美元，超出市场共识预期的 1.22 美元，超出 0.23 美元。西氏医药服务的股本回报率为 18.60%，净利润率为 17.03%。该公司在本季度的收入为 6.98 亿美元，而分析师预期为 6.8524 亿美元。在去年同期，该公司的每股收益为 1.56 美元。该公司的收入同比增长 0.4%。分析师预计西氏医药服务公司本财年的每股收益将达到 6.62 美元。</p>
<h2>西氏医药服务股息公告</h2>
<p>该公司最近还披露了一项季度股息，将于 8 月 6 日（星期三）支付。7 月 30 日（星期三）登记的股东将获得每股 0.21 美元的股息。这相当于年化股息为 0.84 美元，股息收益率为 0.39%。该股息的除息日期为 7 月 30 日（星期三）。西氏医药服务的股息支付比率目前为 13.19%。</p>
<h2>西氏医药服务简介</h2>
<p>（免费报告）</p>
<p>西氏医药服务公司设计、制造和销售用于注射药物和医疗产品的封闭和输送系统，业务覆盖美洲、欧洲、中东、非洲和亚太地区。它分为两个部门，专有产品和合同制造产品。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，而不是西氏医药服务</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>GlobalFoundries 股票触底：反弹即将来临吗？</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>3 只小盘股具有巨大的回报潜力</li>
<li>分析师最爱的比特币矿工 CleanSpark：值得 hype 吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

阿默普莱斯金融

<p>Ameriprise Financial Inc. 在第四季度将其在西氏医药服务公司（NYSE:WST）的持股增加了 21.0%，增持了 29,118 股，总持股达到 167,746 股，价值约为 5490 万美元。其他对冲基金也调整了在 WST 的持仓。分析师对该股票的评级意见不一，普遍评级为 “适度买入”，目标价为 332.50 美元。WST 股票开盘价为 213.39 美元，市值为 153.3 亿美元，市盈率为 31.90。该公司报告每股收益为 1.45 美元，超出预期</p>

<p>Ameriprise Financial Inc. boosted its holdings in West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 21.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,746 shares of the medical instruments supplier's stock after buying an additional 29,118 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.23% of West Pharmaceutical Services worth $54,947,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>阿默普莱斯金融公司在最近向证券交易委员会（SEC）提交的 13F 文件中表示，在第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股增加了 21.0%。该基金在本季度购买了额外的 29,118 股后，持有 167,746 股该医疗器械供应商的股票。截至最近报告期末，阿默普莱斯金融公司持有的西氏医药服务公司约占 0.23%，价值 54,947,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Several other hedge funds have also added to or reduced their stakes in WST. Quadrant Capital Group LLC increased its position in shares of West Pharmaceutical Services by 5.4% during the 4th quarter. Quadrant Capital Group LLC now owns 626 shares of the medical instruments supplier's stock valued at $205,000 after purchasing an additional 32 shares during the last quarter. Baron Wealth Management LLC grew its position in West Pharmaceutical Services by 1.9% during the fourth quarter. Baron Wealth Management LLC now owns 1,926 shares of the medical instruments supplier's stock valued at $631,000 after buying an additional 35 shares during the period. Exchange Traded Concepts LLC increased its holdings in West Pharmaceutical Services by 18.9% during the fourth quarter. Exchange Traded Concepts LLC now owns 239 shares of the medical instruments supplier's stock worth $78,000 after buying an additional 38 shares during the last quarter. Lake Street Advisors Group LLC raised its position in West Pharmaceutical Services by 5.8% in the fourth quarter. Lake Street Advisors Group LLC now owns 711 shares of the medical instruments supplier's stock worth $233,000 after acquiring an additional 39 shares during the period. Finally, Cornerstone Planning Group LLC boosted its stake in West Pharmaceutical Services by 57.1% in the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 40 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金也增加或减少了在 WST 的持股。Quadrant Capital Group LLC 在第四季度将其在西氏医药服务公司的股份增加了 5.4%。Quadrant Capital Group LLC 现在拥有 626 股该医疗器械供应商的股票，价值 205,000 美元，此前在上个季度购买了额外的 32 股。Baron Wealth Management LLC 在第四季度将其在西氏医药服务公司的持股增加了 1.9%。Baron Wealth Management LLC 现在拥有 1,926 股该医疗器械供应商的股票，价值 631,000 美元，此前在该期间购买了额外的 35 股。Exchange Traded Concepts LLC 在第四季度将其在西氏医药服务公司的持股增加了 18.9%。Exchange Traded Concepts LLC 现在拥有 239 股该医疗器械供应商的股票，价值 78,000 美元，此前在上个季度购买了额外的 38 股。Lake Street Advisors Group LLC 在第四季度将其在西氏医药服务公司的持股增加了 5.8%。Lake Street Advisors Group LLC 现在拥有 711 股该医疗器械供应商的股票，价值 233,000 美元，此前在该期间购买了额外的 39 股。最后，Cornerstone Planning Group LLC 在第四季度将其在西氏医药服务公司的持股增加了 57.1%。Cornerstone Planning Group LLC 现在拥有 110 股该医疗器械供应商的股票，价值 38,000 美元，此前在上个季度购买了额外的 40 股。目前 93.90% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>WST has been the topic of a number of research reports. StockNews.com cut shares of West Pharmaceutical Services from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 27th. Stephens upgraded West Pharmaceutical Services to a &#34;strong-buy&#34; rating in a research note on Monday, April 21st. Evercore ISI began coverage on West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an &#34;outperform&#34; rating and a $275.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $250.00 target price for the company in a research report on Friday, February 14th. Finally, KeyCorp lowered their price target on shares of West Pharmaceutical Services from $470.00 to $325.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, West Pharmaceutical Services has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $332.50.</p>
<div class="lb-trans"><p>WST 已成为多份研究报告的主题。StockNews.com 在 2 月 27 日的报告中将西氏医药服务的股票评级从 “买入” 下调至 “持有”。Stephens 在 4 月 21 日的研究报告中将西氏医药服务的评级上调至 “强力买入”。Evercore ISI 在 3 月 18 日的研究报告中开始覆盖西氏医药服务。他们对该股票给予了 “跑赢大盘” 的评级，并设定了 275.00 美元的目标价。德意志银行将西氏医药服务的股票评级从 “持有” 上调至 “买入”，并在 2 月 14 日的研究报告中为该公司设定了 250.00 美元的目标价。最后，KeyCorp 在 2 月 14 日的研究报告中将西氏医药服务的股票目标价从 470.00 美元下调至 325.00 美元，并对该股票给予了 “增持” 评级。两位投资分析师对该股票给予了持有评级，六位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，西氏医药服务的平均评级为 “适度买入”，共识目标价为 332.50 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年将推动标准普尔 500 表现的因素是什么？</li>
</ul>
</div><p><strong>Get Our Latest Analysis on West Pharmaceutical Services</strong></p>
<div class="lb-trans"><p><strong>获取我们对西氏医药服务的最新分析</strong></p>
</div><h2>West Pharmaceutical Services Stock Down 0.6 %</h2>
<div class="lb-trans"><h2>西氏医药服务股票下跌 0.6%</h2>
</div><p>Shares of NYSE:WST opened at $213.39 on Friday. The firm has a fifty day moving average price of $216.55 and a two-hundred day moving average price of $278.35. The company has a market cap of $15.33 billion, a price-to-earnings ratio of 31.90, a PEG ratio of 6.74 and a beta of 1.14. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $367.71.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST）周五开盘价为 213.39 美元。该公司的 50 日移动平均价格为 216.55 美元，200 日移动平均价格为 278.35 美元。公司市值为 153.3 亿美元，市盈率为 31.90，PEG 比率为 6.74，贝塔值为 1.14。公司的债务与股本比率为 0.08，流动比率为 2.79，速动比率为 2.23。西氏医药服务公司的一年低点为 187.43 美元，一年高点为 367.71 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its earnings results on Thursday, April 24th. The medical instruments supplier reported $1.45 EPS for the quarter, topping the consensus estimate of $1.22 by $0.23. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. The business had revenue of $698.00 million during the quarter, compared to analysts' expectations of $685.24 million. During the same period in the previous year, the business earned $1.56 earnings per share. The firm's revenue was up .4% on a year-over-year basis. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）最近在 4 月 24 日发布了其财报。该医疗器械供应商报告本季度每股收益为 1.45 美元，超出市场共识预期的 1.22 美元，超出 0.23 美元。西氏医药服务的股本回报率为 18.60%，净利润率为 17.03%。该公司在本季度的收入为 6.98 亿美元，而分析师预期为 6.8524 亿美元。在去年同期，该公司的每股收益为 1.56 美元。该公司的收入同比增长 0.4%。分析师预计西氏医药服务公司本财年的每股收益将达到 6.62 美元。</p>
</div><h2>West Pharmaceutical Services Dividend Announcement</h2>
<div class="lb-trans"><h2>西氏医药服务股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 6th. Stockholders of record on Wednesday, July 30th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.39%. The ex-dividend date of this dividend is Wednesday, July 30th. West Pharmaceutical Services's dividend payout ratio is currently 13.19%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度股息，将于 8 月 6 日（星期三）支付。7 月 30 日（星期三）登记的股东将获得每股 0.21 美元的股息。这相当于年化股息为 0.84 美元，股息收益率为 0.39%。该股息的除息日期为 7 月 30 日（星期三）。西氏医药服务的股息支付比率目前为 13.19%。</p>
</div><h2>West Pharmaceutical Services Profile</h2>
<div class="lb-trans"><h2>西氏医药服务简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.</p>
<div class="lb-trans"><p>西氏医药服务公司设计、制造和销售用于注射药物和医疗产品的封闭和输送系统，业务覆盖美洲、欧洲、中东、非洲和亚太地区。它分为两个部门，专有产品和合同制造产品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是西氏医药服务</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>GlobalFoundries 股票触底：反弹即将来临吗？</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>3 只小盘股具有巨大的回报潜力</li>
<li>分析师最爱的比特币矿工 CleanSpark：值得 hype 吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿默普莱斯金融公司购入了西氏医药服务公司（NYSE: WST）的 29,118 股股票